All In Biotech

Drug Trial Radar · NCT04589403

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

A Phase 1a/1b Study of OPT101 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Feb 18, 2021

Primary completion

Sep 27, 2021

Study completion Sep 27, 2021

Sponsor

Lead sponsor
Op-T LLCIndustry
Sponsor type
Industry
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.

Conditions

  • Healthy

Interventions

  • OPT101Drug

    15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)Time frame: 21 days
  2. Rate and type of adverse events during and after infusion of OPT101 or placeboTime frame: 48 hours
  3. Incidence of vital signsTime frame: 48 hours
  4. Incidence of abnormal laboratory valuesTime frame: 21 days
  5. Definition of maximum tolerated (MTD) single and repeated doses of OPT101Time frame: 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • IMMUNOe Research

    Centennial, Colorado

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.